Brief: Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six Months
29/07/2026 12:35
BRIEF-Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six Months July 29 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:
EXPECTS REVENUE OF RMB311 MILLION-RMB436 MILLION FOR SIX MONTHS ENDED JUNE 30, 2026, UP 200%-320% Y/Y
EXPECTED HY REVENUE GROWTH MAINLY DRIVEN BY MADRIGAL PHARMACEUTICALS AND BOEHRINGER INGELHEIM COLLABORATIONS
Further company coverage: 6938.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Suzhou Ribo Life Science
See all newsBrief: Suzhou Ribo Life Science To Buy Remaining 49.71% Of Target Company
Suzhou Ribo climbs on EU clinical trials application of RBD3133 for obesity
Brief: Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six Months
Brief: Suzhou Ribo Life Science Says EMA Approves Initiation Of Phase 2B Trial Of Vortosiran
CEO Purchases 6800 H Shares On Open Market